The landmark ruling against BNP Paribas has fundamentally changed the risk landscape for banks. Financial institutions can no longer treat compliance failures as just costly fines - they now face direct liability for human rights violations.
Unlike market-driven themes, this regulatory shift creates sustained demand regardless of economic cycles. Banks must invest in compliance technology to protect themselves from catastrophic legal exposure.
These companies provide the critical backbone for modern financial compliance - from sanctions screening to anti-money laundering. As regulatory requirements intensify, their solutions become increasingly indispensable.
Summary of the basket's total market capitalisation and concentration among top holdings.
FICO: $38.79B
PAYC: $11.29B
BL: $3.08B
A landmark legal ruling holding a major bank liable for aiding genocide has created a powerful catalyst for the regulatory technology sector. This precedent means financial institutions now face catastrophic legal risks beyond traditional fines, driving urgent demand for advanced compliance and risk management solutions.
This group focuses on RegTech companies that provide critical software and services for anti-money laundering, sanctions screening, and customer verification. These are non-cyclical businesses positioned to benefit from a structural shift in how banks approach compliance and risk management.
These companies were handpicked as key players in the regulatory technology space, offering the solutions that financial institutions will need to strengthen their compliance frameworks. They represent tactical exposure to a theme driven by legal precedent rather than market cycles.
A U.S. jury found BNP Paribas liable for aiding genocide in Sudan, setting a historic precedent for bank accountability. This ruling is expected to drive a surge in spending on regulatory technology as financial institutions rush to upgrade their compliance and risk management systems to avoid similar catastrophic legal consequences.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Published on October 20
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
On average, analysts expect assets in this group to grow 49.19% over the next year.
10 of 13 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+49.19%
